Nebilox (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. It also stimulates nitric‑oxide release from the endothelium, causing vasodilation. The combined effect reduces peripheral resistance and arterial pressure, providing effective antihypertensive action.

The specific dose of Nebilox is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Dosage adjustments are made according to blood pressure targets and tolerability, and the prescriber provides the exact regimen.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nebilox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebivolol is a third‑generation, β1‑selective blocker with additional nitric‑oxide‑mediated vasodilation, which may offer better tolerability and fewer metabolic side effects compared with older non‑selective beta blockers. Its unique profile can be advantageous in patients who need both blood‑pressure control and improved endothelial function.

Nebilox should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Nebilox is taken orally, usually once daily, with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, symptomatic hypotension, atrioventricular block, bronchospasm in patients with reactive airway disease, and rare allergic reactions. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, difficulty breathing, or signs of an allergic response.

Nebilox is contraindicated in patients with known hypersensitivity to nebivolol or any component of the formulation, those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, and individuals with uncompensated heart failure. Clinicians should assess each patient’s medical history before prescribing.